Toshiba Medical’s Premium Ultrasound Platform Enables Fast and Safe Liver Imaging

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Physicians now have the powerful imaging technology they need for fast, safe and reliable evaluation of liver lesions with the premium Aplio™ i-series ultrasound platform from Toshiba Medical, a Canon Group company. With the recent expansion of LI-RADS® (Liver Imaging Reporting and Data System) to include contrast-enhanced ultrasound (CEUS)* imaging for hepatocellular carcinoma (HCC) characterization, the Aplio i-series offers an ideal solution for confident diagnoses.

Offering healthcare providers a more cost-effective, less invasive and safer solution than other radiation emitting modalities, the Aplio i-series is a highly-advanced and scalable ultrasound solution made up of the Aplio i700 and Aplio i800. Health systems, such as UC San Diego Health, are using the Aplio i-series’ imaging resolution and penetration, and comprehensive CEUS imaging and quantification package, to assess perfusion dynamics in the liver and help improve HCC surveillance results.

Quality Image/Quality Diagnosis:  Dan Skyba, director, Ultrasound Business Unit, Toshiba America Medical Systems, Inc. said, “The Aplio i-series offers the superb image quality clinicians need to make confident diagnosis and provide excellent patient care.”  He concluded, “Combining a brand new system architecture with matrix transducer technology and a world-renown CEUS imaging package, these premium systems offer best in class resolution, penetration and dynamic contrast visualization. The Aplio i-series facilitates small HCC diagnosis and surveillance, even in obese or difficult to image patients, while improving workflow and keeping patients safe and more comfortable. As the transition to a value-based healthcare system continues, the use of CEUS for characterization of focal liver lesions is an example of a cost-effective and high-value clinical solution.”

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.